Navigation Links
Ardelyx Reports Second Quarter 2014 Financial Results
Date:8/7/2014

ient in the Phase 2b ESRD clinical trial in hyperphosphatemia which commenced in April 2014.  These payments are being recognized ratably over our expected period of performance under the agreement, which is estimated to conclude on December 31, 2016. 

Collaborative development revenue, which is comprised of development expenses that are reimbursable to Ardelyx by AstraZeneca, was $2.6 million for the three months ended June 30, 2014 compared to $5.3 million for the three months ended June 30, 2013 primarily attributable to the completion of certain activities related to the clinical trials that are a part of the AstraZeneca agreement.

Research and development expenses were $5.2 million for the three months ended June 30, 2014 compared to $7.2 million for the three months ended June 30, 2013. The decrease was primarily driven by a $2.6 million decrease in development activities conducted by Ardelyx on behalf of AstraZeneca in accordance with the AstraZeneca agreement, from $5.2 million for the three months ended June 30, 2013 to $2.6 million in same period in 2014. This was offset by increased discovery research expenses of $0.5 million due to increased research activities for non-partnered programs.

General and administrative expenses were $1.2 million for the three months ended June 30, 2014 compared to $0.9 million for the three months ended June 30, 2013. The increase was primarily due to an increase in professional services fees and an increase of personnel-related expenses.

For the three months ended June 30, 2014, the Company recorded $0.1 million of stock based compensation.

On June 30, 2014, the Company had $117.8 million in cash and cash equivalents compared to $34.4 million on December 31, 2013, an increase of $83.4 million.  The Company has no outstanding debt as of June 30, 2014.  On June 30, 2014, the Company had 18,335,620 shares of common stock issued and outstanding.

About Ardelyx,
'/>"/>

SOURCE Ardelyx, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
2. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
3. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
4. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
5. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
6. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
7. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
8. Luminex Corporation Reports First Quarter 2012 Results
9. Hospira Reports First-Quarter 2012 Results
10. Endo Reports First Quarter Financial Results And Announces Return To Steady Supply Of OPANA® ER And Voltaren® Gel
11. The Female Health Company Reports Second Quarter Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 16, 2014 This report analyzes the worldwide markets ... following Product Segments: SPECT Systems (Includes SPECT and SPECT/CT systems), ... provides separate comprehensive analytics for the US, Canada ... , Asia-Pacific , Latin ... forecasts are provided for the period 2013 through 2020. Also, ...
(Date:9/16/2014)... 2014 3SBio Inc., ("3SBio") a leading ... focusing on researching, developing, manufacturing and marketing ... into an exclusive license agreement with JenKem Technology ... marketing in Mainland China of PEG-irinotecan, a long-acting ... is over-expressed in many solid tumors, including colorectal, ...
(Date:9/16/2014)... The Pulmonary Fibrosis Foundation (PFF) announced today ... 1,100 patients and families suffering from pulmonary fibrosis (PF) ... the Patient-Focused Drug Development Meeting for Idiopathic Pulmonary Fibrosis ... to seek patient input in order to better understand ... "We applaud the FDA for focusing its attention on ...
Breaking Medicine Technology:Global Nuclear Medicine Imaging Equipment Industry 2Global Nuclear Medicine Imaging Equipment Industry 3Global Nuclear Medicine Imaging Equipment Industry 4Global Nuclear Medicine Imaging Equipment Industry 5Global Nuclear Medicine Imaging Equipment Industry 6Global Nuclear Medicine Imaging Equipment Industry 7Global Nuclear Medicine Imaging Equipment Industry 8Global Nuclear Medicine Imaging Equipment Industry 9Global Nuclear Medicine Imaging Equipment Industry 10Global Nuclear Medicine Imaging Equipment Industry 11Global Nuclear Medicine Imaging Equipment Industry 12Global Nuclear Medicine Imaging Equipment Industry 13Global Nuclear Medicine Imaging Equipment Industry 14Global Nuclear Medicine Imaging Equipment Industry 15Global Nuclear Medicine Imaging Equipment Industry 16Global Nuclear Medicine Imaging Equipment Industry 17Global Nuclear Medicine Imaging Equipment Industry 18Global Nuclear Medicine Imaging Equipment Industry 19Global Nuclear Medicine Imaging Equipment Industry 20Global Nuclear Medicine Imaging Equipment Industry 21Global Nuclear Medicine Imaging Equipment Industry 22Global Nuclear Medicine Imaging Equipment Industry 23Global Nuclear Medicine Imaging Equipment Industry 24Global Nuclear Medicine Imaging Equipment Industry 25Global Nuclear Medicine Imaging Equipment Industry 263SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 23SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 33SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 43SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 5PFF Submits Survey Data From More Than 1,100 Pulmonary Fibrosis Patients And Families To U.S. Food And Drug Administration For Upcoming Drug Development Meeting 2PFF Submits Survey Data From More Than 1,100 Pulmonary Fibrosis Patients And Families To U.S. Food And Drug Administration For Upcoming Drug Development Meeting 3PFF Submits Survey Data From More Than 1,100 Pulmonary Fibrosis Patients And Families To U.S. Food And Drug Administration For Upcoming Drug Development Meeting 4
... Misonix, Inc. (NASDAQ: MSON ), a ... innovative therapeutic ultrasonic products worldwide for wound debridement, ... other surgical applications, has entered into a new, ... SANTE (SES) of Algiers, Algeria for the distribution ...
... BME (BioMedical Enterprises, Inc.), a developer and manufacturer ... United States launch of Speed™. It is the first ... to orthopaedic and podiatric surgeons. BME, the ... its extensive knowledge in memory metal implant design to ...
Cached Medicine Technology:Misonix Announces New Distribution Agreement for Algeria 2Misonix Announces New Distribution Agreement for Algeria 3
(Date:9/16/2014)... 2014 Keep that sexy decolletage as you ... neck. , "The Face Whisperer Neck & Decollete Cream ... Heshelow, founder of Sublime Beauty®. "It contains rich ingredients to ... and arnica." , A special ingredient is Argireline, known as ... rich anti-aging cream comes in an airless pump bottle, and ...
(Date:9/16/2014)... Holganix, an elite member of the ... in the country, produces an organic Bionutritional product that ... naturally decreasing disease and insect damage though significant root ... will hold its third annual Bionutritional Summit at the ... from 1:00 P.M. through 6:00 P.M., the day before ...
(Date:9/16/2014)... 2014; San Francisco) In a healthcare climate ... against potential benefit, a Yale study has found ... radiation procedures on elderly women with early-stage breast ... at the 56th annual conference of the American ... 131: Evaluating National Practice in Radiotherapy for Elderly ...
(Date:9/16/2014)... Pulmonary Hypertension Association Travels to San Diego for ... Patients and Families to Help Fight Rare Lung Disease , ... pulmonary hypertension association that works to find ways to prevent ... lungs that affects the functioning of the heart and can ... only 2.8 years. , What:, PHA On The ...
(Date:9/16/2014)... -- Modern forensic techniques are shedding light on a ... Richard III, the last English monarch to die in ... remains, using whole-body CT scans and micro-CT imaging of ... injuries he suffered at the Battle of Bosworth Field, ... modern forensics revealed that two skull injuries could have ...
Breaking Medicine News(10 mins):Health News:15% Off Face Whisperer® Neck & Decollete Cream Now from Sublime Beauty; Care For This Delicate Skin That Shows Age Quickly 2Health News:Holganix Holds 3rd Annual Bionutrional Summit in Louisville, Kentucky 2Health News:Pulmonary Hypertension Association Travels to San Diego for PHA On The Road to Help Fight Rare Lung Disease 2Health News:Pulmonary Hypertension Association Travels to San Diego for PHA On The Road to Help Fight Rare Lung Disease 3Health News:Modern Forensics Provides Clues to Death of Richard III 2
... MEDai, Inc., headquartered in,Orlando, FL, a leading ... longstanding Pinpoint Quality(TM) client, Sharp,HealthCare of San ... Baldrige National,Quality Award., The Baldrige award ... quality and organizational performance excellence. Congress,established the ...
... of Medical Administration Lauds and ... ... /Xinhua-PRNewswire-FirstCall/ -- Linkwell,Corporation (OTC Bulletin Board: LWLL), a leading ... announced,today that its Chairman and CEO, Mr. Xuelian Bian ...
... in PSAs for personal health record awareness, ... Information,Management Association (AHIMA) launched the "It,s HI Time, ... on the,importance of improving the management of their ... This campaign encourages Americans -- especially caregivers, maturing,adults, ...
... It,s a fact of life that everyone,has problems. But, ... others. Those with mental illness, addiction, or,HIV/AIDS often face ... don,t understand. Dealing with illness is often a lonely,heartbreaking ... those who battle such things have an online hub ...
... 28 In a reversal of what has,become the ... interactive training coupled with two hours of live phone,tech ... EZM Web,customers., EZM Web tracks and controls maintenance ... plus inventory control via the Web. It is accessible,from ...
... (Nasdaq: IACI ),announced today that it has ... (http://www.healthcentral.com ), a leading collection of,health and ... of,the deal have not been disclosed., The ... 30 owned and,operated condition-specific and healthy living websites ...
Cached Medicine News:Health News:MEDai Client Named Recipient of 2007 Malcolm Baldrige National Quality Award 2Health News:MEDai Client Named Recipient of 2007 Malcolm Baldrige National Quality Award 3Health News:Linkwell Chairman & CEO Addresses the Association of Chinese Nosocomial Infections Professional Committee 2Health News:Linkwell Chairman & CEO Addresses the Association of Chinese Nosocomial Infections Professional Committee 3Health News:AHIMA Launches National PHR Consumer Awareness Campaign 2Health News:WebTribes Offers Online Home for Those with Illnesses 2Health News:Maintenance Software Company Bucks Trend, Offers Unlimited No-Charge Product Tech Support 2Health News:IAC Acquires a Minority Stake in The HealthCentral Network 2Health News:IAC Acquires a Minority Stake in The HealthCentral Network 3
Used in the peritoneal cavity to remove large volumes of thick exudate....
100cc silicone evacuator...
Used following open gallbladder procedure to drain bile. Often attached to Bard bile bag....
Used following open gallbladder procedure to drain bile. Often attached to Bard bile bag....
Medicine Products: